Sign In
Buy AMPE
$0.183
+0 (+0%)
At Close: Jun 03, 2026
Noven Financial Group, Inc. Buys iShares 7-–… Year Treasury Bond ETF, iShares '-7 Year ...
12:00am, Friday, 01'st May 2020Finding The Kink In COVID-19's Armor - Preventing ARDS
07:42am, Tuesday, 28'th Apr 2020
A treatment is needed for ARDS. Remdesivir was touted by STAT. Antiviral efficacy and side effects are under scrutiny. CytoDyn is closest to a trial readout.
Ampio (AMPE) Looks Good: Stock Adds 5.2% in Session
12:37pm, Thursday, 16'th Apr 2020
Ampio (AMPE) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Implied Volatility Surging for Ampio (AMPE) Stock Options
02:41pm, Thursday, 02'nd Apr 2020
Investors need to pay close attention to Ampio (AMPE) stock based on the movements in the options market lately.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co
Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat ...
12:00am, Thursday, 02'nd Apr 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE; the "Company"), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient enrollment in its Phase 3 clin
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory co
Ampio Suspends Patient Enrollment in its Phase ' Study of Ampion for Severe Osteoarthritis of ...
12:00am, Tuesday, 24'th Mar 2020Ampio Provides Corporate Update
11:30am, Friday, 21'st Feb 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial titled "Evaluating the Efficac
